hERG Channel Trafficking Screening

Cambridge Bioscience offers access to a hERG channel trafficking screening service from ChanTest. This high throughput, non-electrophysiological screening service utilises the assay HERG-Lite®, enabling the assessment of hERG risk.

HERG-Lite®
HERG-Lite® is a unique, rapid and cost-effective assay that monitors hERG expression at the cell surface. Trafficking-associated decreases in hERG activity occur hours after exposure to large and small drug molecules, but are as important to assessing risk as direct block. HERG-Lite® identifies hERG trafficking inhibitors by exposing wild-type (WT) hERG to drug overnight, and hERG channel blockers by measuring rescue of a trafficking-defective mutant hERG (SM) cell line.

Features of the hERG Channel Trafficking Screening Service
• Detects large & small drug molecules that produce hERG risk by inhibiting protein trafficking from the endoplasmic reticulum
• Identifies large & small drug molecules that block hERG directly
• Fully validated against known hERG trafficking inhibitors
• Widely tested on over 1,000 large & small drug molecules
• Large & small drug molecules are run at 3 concentrations in triplicate
• Rapid results provided 48 hours after study completion

Request A No Obligation Quote
To discuss a hERG channel trafficking screening project, please contact our experienced team by Clicking Here